SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Akamai Technologies, Inc. engages in the provision of cloud services for delivering, optimizing, and securing content and business applications over the Internet. Its products include security, web performance, media delivery, and network operator. The company was founded by Frank T. Leighton, Jonathan Seelig, Randall S. Kaplan, and Daniel M. Lewin on August 20, 1998 and is headquartered in Cambridge, MA.

Akamai Technologies Inc

Akamai is trending following a Q3 earnings beat, driven by strong security and cloud computing growth, fueling discussions about the company's ongoing transformation. Community members are reacting positively to the results and raised guidance, with some analysts increasing price targets. The company's expansion in edge computing and AI is also a key talking point.

Petróleo Brasileiro SA engages in oil and gas exploration, production, and distribution activities. It operates through the following segments: Exploration and Production; Refining, Transportation, and Marketing; and Gas and Low Carbon Energies. The Exploration and Production segment covers the activities of exploration, development, and production of crude oil, natural gas liquid, and natural gas, for the primary purpose of supplying its domestic refineries. The Refining, Transportation, and Marketing segment refers to refining, logistics, transport, and trading of crude oil and oil products activities as well as exports of ethanol. The Gas and Low Carbon Energies represents the activities of logistic and trading of natural gas and electricity, transportation and trading of liquefied natural gas, generation and electricity by means of thermoelectric power plants, as well as holding interests in transporters and distributors of natural gas. The company was founded on October 3, 1953 and is headquartered in Rio de Janeiro, Brazil.

Petroleo Brasileiro S.A. Petrobras - ADR

Petroleo Brasileiro

PBR is trending as investors discuss the upcoming ex-dividend date and the potential payout amount, with some expressing excitement and others confusion regarding the details. Community members are also weighing whether to hold the stock long-term for dividends or take profits, considering factors like oil prices and the broader market context. Recent reports of earnings and leading the charge through key resistance is also driving interest.

LyondellBasell Industries NV engages in the refinery and production of plastic resins and other chemicals. It operates through the following segments: Olefins and Polyolefins-Americas; Olefins and Polyolefins-Europe, Asia, International; Intermediates and Derivatives; Advanced Polymer Solutions; Refining; and Technology. The Olefins and Polyolefins-Americas segment produces and markets olefins and co-products, polyethylene and polypropylene. The Olefins and Polyolefins-Europe, Asia, International segment also offers olefins and polyolefins. The Intermediates and Derivatives segment includes propylene oxide and its derivatives; oxyfuels and related products; and intermediate chemicals. The Advanced Polymer Solutions segment produces and markets compounding and solutions, such as polypropylene compounds, engineered plastics, masterbatches, colors and powders, engineered composites, and advanced polymers. The Refining segment refines heavy, high-sulfur crude oil and other crude oils of varied types and sources. The Technology segment develops chemical and polyolefin process technologies and manufactures and sells polyolefin catalysts. The company was founded in December 2007 and is headquartered in London, the United Kingdom.

LyondellBasell Industries NV - Ordinary Shares - Class A

LYB is trending due to recent price declines and upcoming earnings, with investors closely watching whether the company will maintain its dividend. The community is debating the stock's valuation, potential for a turnaround, and whether current prices present a buying opportunity or signal further downside. Discussions also include the broader impact of economic conditions and sector-specific challenges on LYB's performance.

The GEO Group, Inc. engages in the design, financing, development, and support services for secure facilities, processing centers, and community re-entry facilities. It operates through the following segments: U.S. Secure, Electronic Monitoring and Supervision, Reentry, and International Services. The U.S. Secure Services segment encompasses the United States-based public-private partnership corrections and detention business. The Electronic Monitoring and Supervision Services segment conducts its services in the U.S. The Reentry Services Segment consists of various community-based and reentry services. The International Services segment consists of public-private partnership secure services operations in Australia and South Africa. The company was founded by George C. Zoley in 1984 and is headquartered in Boca Raton, FL.

Geo Group, Inc.

GEO Group is trending due to a mix of factors including record high ICE detainee populations and analyst upgrades, with community members weighing in on potential future price movements and government contracts. Discussions also involve share buybacks and comparing GEO's performance to similar companies, along with the impact of potential policy changes. Option traders are active, speculating on future gains with calls expiring in 2027.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinz is trending amid speculation about a potential breakup, with discussions focusing on whether this could unlock shareholder value or if debt concerns remain. The company's attractive dividend yield is also a key point, with some viewing it as a safe, inflation hedge play, while others express skepticism about long-term growth.

Icahn Enterprises LP operates as holding company. It operates through following eight business segments: Investment, Automotive, Energy, Food Packaging, Metals, Real Estate, Home Fashion, and Pharma. The Investment segment consists of various private investment funds. The Automotive segment holds ownership in Icahn Automotive Group LLC. The Energy segment holds ownership in CVR Energy, Inc., which owns majority interests in two separate operating subsidiaries, CVR Refining, LP and CVR Partners, LP. The Food Packaging segment holds ownership in Viskase Cos., Inc., which is engaged in the production and sale of cellulosic, fibrous, and plastic casings for the processed meat and poultry industry. The Metals segment operates through PSC Metals, Inc., which engages in the business of collecting, processing, and selling ferrous and non-ferrous metals, as well as the processing and distribution of steel pipe and plate products in the Midwest and Southern U.S. The Real Estate segment consists of rental real estate, property development and resort activities. The Home Fashion segment operates through WestPoint Home LLC, which consists of manufacturing, sourcing, marketing, distributing, and selling home fashion consumer products. The Pharma segments operates through Vivus, Inc., a specialized pharmaceutical company. The company was founded on February 17, 1987 and is headquartered in Sunny Isles Beach, FL.

Icahn Enterprises L P - Unit

Icahn Enterprises, L.P.

Icahn Enterprises is trending as investors discuss its high dividend yield and upcoming earnings report, focusing on whether the distribution will be maintained. Community members are analyzing Carl Icahn's investment strategies and potential impacts from holdings like CVR Energy, with some speculating about a potential short squeeze. The stock's volatile history and recent performance are driving both bullish and bearish sentiment within the investment community.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending amidst a debate on its potential, with some traders calling it a "sucker coin" while others anticipate a rally, possibly fueled by staking rewards and broader market catalysts. Community chatter revolves around identifying entry and exit points, with strong opinions on both bullish and bearish scenarios. Sentiment appears mixed as some warn of further downside, while others look for a breakout.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

$GRAL is trending amid community excitement around its cancer detection technology, with discussions focused on recent study results and potential FDA approval. Investors are also closely monitoring developments, including Samsung's investment and partnerships, while weighing competition and regulatory hurdles. Some traders are pointing to technical indicators and options activity.

Expedia Group, Inc. is an online travel company, which engages in the provision of travel products and services to leisure and corporate travelers. It operates through the following segments: B2C, B2B, and Trivago. The B2C segment offers a full range of travel and advertising services to worldwide customers through a variety of consumer brands. The B2B segment refers to a wide range of travel and non-travel companies including airlines, offline travel agents, online retailers, corporate travel management, and financial institutions. The Trivago segment generates advertising revenue primarily from sending referrals to online travel companies and travel service providers from hotel metasearch websites. The company was founded in 1994 and is headquartered in Seattle, WA.

Expedia Group Inc

Expedia Group is trending amid speculation of a potential acquisition by Uber, fueling discussions around industry consolidation and Khosrowshahi's history with both companies. While some community members express skepticism about the deal's strategic alignment, others point to Expedia's attractive valuation and potential synergies within a super app ecosystem. Bullish sentiment is further supported by analysts raising price targets and highlighting Expedia's strong B2B growth.

The Filecoin network achieves staggering economies of scale by allowing anyone worldwide to participate as storage providers. It also makes storage resemble a commodity or utility by decoupling hard-drive space from additional services. On this robust global market the price of storage will be driven by supply and demand, not corporate pricing departments, and miners will compete on factors like reputation for reliability as well as price.

Filecoin

Filecoin ($FIL) is trending with high volume, sparking community excitement about a potential breakout and a run towards previous all-time highs. Discussions center on its utility as decentralized storage competing with Amazon AWS, driving interest as investors see it as a value play. Comparisons to other cryptocurrencies, like $ZEC, and the anticipation of an alt season further fuel the upward momentum.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Delta Financial Advisors LLC Buys 3,611 Shares of Merck & Co., Inc. $MRK

Delta Financial Advisors LLC boosted its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 43.6% during the 2nd quarter, according to its most recent 13F filing with the SEC. The firm...

Merck & Co., Inc. (NYSE:MRK) Upgraded at Wall Street Zen

Wall Street Zen raised Merck & Co., Inc. from a "hold" rating to a "strong-buy" rating in a report on Saturday...

Harvest Portfolios Group Inc. Increases Position in Merck & Co., Inc. $MRK

Harvest Portfolios Group Inc. increased its stake in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 9.5% during the second quarter, according to the company in its most recent disclosure...

Here is What to Know Beyond Why Merck & Co., Inc. (MRK) is a Trending Stock

Zacks.com users have recently been watching Merck (MRK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Moderna Q3 Earnings Beat, Stock Up on Revised '25 Spending Plans

MRNA posts narrower-than-expected Q3 loss and lifts liquidity outlook for 2025, as cost cuts and revised spending plans boost investor sentiment

AZN Q3 Earnings Top Estimates, Sales Rise As Most Key Drugs Outperform

AstraZeneca posts strong Q3 results. Core earnings and revenues beat estimates as key drugs like Tagrisso, Imfinzi and Farxiga fuel broad-based growth.

<ul class="summary-bullets"><li>Merck is currently evaluating Sac-TMT in 15 global late-stage trials spanning six tumor types, including breast, endometrial, and lung cancers.</li><li>Separately, the company also said that it has now assumed full responsibility for the development of MK-8690, an investigational drug targeting inflammatory bowel diseases.&nbsp;<br>&nbsp;</li></ul><p>Shares of Merck (MRK) traded 1% higher on Tuesday afternoon after the company said that it has entered into a funding agreement with Blackstone Life Sciences to advance its experimental cancer drug.</p><p>Under the <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.merck.com/news/merck-enters-into-research-and-development-funding-agreement-with-blackstone-life-sciences-for-sacituzumab-tirumotecan-sac-tmt/">deal</a>, Blackstone will pay Merck $700 million to fund a portion of the development costs for Sacituzumab Tirumotecan or Sac-TMT, an investigational antibody-drug conjugate. An antibody-drug conjugate (ADC) is a type of cancer therapy that combines a targeted antibody with a chemotherapy drug to deliver the drug directly to cancer cells, minimizing damage to healthy cells.</p><h2 class="st-heading-2">Terms Of The Funding Deal</h2><p>Merck is currently evaluating the drug in 15 global late-stage trials spanning six tumor types, including breast, endometrial, and lung cancers. The funding agreement will help fund a portion of the development costs in 2026.</p><p>Blackstone, in return, will be eligible to receive low-to-mid single-digit royalties on net sales of the drug contingent upon receipt of regulatory approval in the U.S. for first-line treatment of triple-negative breast cancer. Blackstone, however, will not receive any right to the drug.</p><p>Sac-TMT was developed by Sichuan Kelun Pharmaceutical Co. The company granted Merck the exclusive rights to develop, manufacture, and commercialize sac-TMT in all territories outside of Greater China, including Mainland China, Hong Kong, Macau, and Taiwan, under a deal.</p><h2 class="st-heading-2">Merck Assumes Responsibility For MK-8690</h2><p>Separately, Merck <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.merck.com/news/merck-signs-agreement-with-dr-falk-pharma-gmbh-for-certain-development-and-commercialization-rights-to-mk-8690-pra-052-an-investigational-anti-cd30-ligand-monoclonal-antibody/">announced</a> on Tuesday that it has reached an agreement through a unit with Germany’s Dr. Falk Pharma GmbH to discontinue a contract signed in 2020 concerning co-development and co-commercialization rights in certain territories for MK-8690, an investigational drug targeting inflammatory bowel diseases. Merck has now assumed full responsibility for the development program.</p><p>Dr. Falk will receive $150 million upfront as part of the deal termination and will continue to be eligible to receive payments associated with development milestones, as well as royalties on sales in certain territories.</p><p>Merck said that it will record a pre-tax charge to research and development expenses of $150 million, or approximately $0.05 per share, in its fourth quarter results as a result of the discontinuation of the deal.</p><h2 class="st-heading-2">How Did Stocktwits Users React?</h2><p>On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/MRK">MRK stock</a> stayed within the ‘bullish’ territory over the past 24 hours, while message volume stayed at ‘high’ levels.</p><figure class="image"><img style="aspect-ratio:624/63;" src="data:image/png;base64,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" width="624" height="63" alt="MRK's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Nov. 4, 2025 | Source: Stocktwits"><figcaption>MRK's Sentiment Meter and Message Volume as of 2:24 p.m. ET on Nov. 4, 2025 | Source: Stocktwits</figcaption></figure><p><br>MRK stock is down 16% this year and approximately 18% over the past 12 months.&nbsp;</p><p>Read also: <a href="https://stocktwits.com/news-articles/markets/equity/evok-stock-doubled-in-value-post-qol-medical-deal/cL28jriR36q">EVOK Stock Doubled In Value Today Post QOL Medical Deal, But Still Fails To Hit $11 Mark</a></p><p><i>For updates and corrections, email newsroom[at]stocktwits[dot]com.</i></p>

Medicine pill is seen with Merck logo displayed on a screen in the background in this illustration photo taken in Poland on November 5, 2021. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

Merck Stock Rises Upon Receipt Of $700M In Funding For Experimental Cancer Drug

The deal will fund a portion of the development costs for Sacituzumab Tirumotecan, also known as Sac-TMT. 

Equity

The deal will fund a portion of the development costs for Sacituzumab Tirumotecan, also known as Sac-TMT. 


Stock Market News for Nov 4, 2025

Wall Street ended mostly higher, with the Nasdaq and the S&P 500 finishing in positive territory, as investors once again flocked to artificial intelligence (AI) stocks following the announcement of a spate of new deals.

Why Merck (MRK) is a Top Value Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Should You Buy Moderna Stock Ahead of Q3 Earnings Report?

MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

$ASTS

$RKLB

$BBAI

$NBIS

Which earnings release are you most excited for the week of Nov. 10? 
 
Drop a comment for others.

MRK
Merck & Co Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest MRK News

MRKMerck & Co Inc